89bio, Inc.

NasdaqGM:ETNB Stock Report

Market Cap: US$2.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

89bio Management

Management criteria checks 2/4

89bio's CEO is Rohan Palekar, appointed in Jul 2018, has a tenure of 7.25 years. total yearly compensation is $7.62M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $5.66M. The average tenure of the management team and the board of directors is 3.8 years and 5.2 years respectively.

Key information

Rohan Palekar

Chief executive officer

US$7.6m

Total compensation

CEO salary percentage8.48%
CEO tenure7.3yrs
CEO ownership0.2%
Management average tenure3.8yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition

Sep 18

Is 89bio (NASDAQ:ETNB) A Risky Investment?

May 22
Is 89bio (NASDAQ:ETNB) A Risky Investment?

89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development

Apr 17

89bio's Pegozafermin Is Now Gaining Momentum

Jan 30

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

Jan 13

89bio: Surviving A Competitive Space - For Now

Oct 29

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

Sep 26
Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

89bio Still Has A Chance As NASH Race Heats Up

Oct 06

89bio completes enrollment in phase 2 trial for NASH treatment

Aug 18

89Bio rallies on Deep Track Capital disclosing 10% stake

Jul 07

CEO Compensation Analysis

How has Rohan Palekar's remuneration changed compared to 89bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$450m

Mar 31 2025n/an/a

-US$387m

Dec 31 2024US$8mUS$646k

-US$367m

Sep 30 2024n/an/a

-US$289m

Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$165m

Dec 31 2023US$6mUS$611k

-US$142m

Sep 30 2023n/an/a

-US$127m

Jun 30 2023n/an/a

-US$119m

Mar 31 2023n/an/a

-US$105m

Dec 31 2022US$3mUS$588k

-US$102m

Sep 30 2022n/an/a

-US$104m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$101m

Dec 31 2021US$5mUS$565k

-US$90m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$5mUS$530k

-US$49m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$60m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$1mUS$431k

-US$57m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$30m

Dec 31 2018US$708kUS$195k

-US$18m

Compensation vs Market: Rohan's total compensation ($USD7.62M) is above average for companies of similar size in the US market ($USD5.43M).

Compensation vs Earnings: Rohan's compensation has increased whilst the company is unprofitable.

CEO

Rohan Palekar (59 yo)

7.3yrs
Tenure
US$7,619,426
Compensation

Mr. Rohan Palekar serves as the Chief Executive Officer and Director at 89bio, Inc. since July 16, 2018. He is an Independent Director at Neoleukin Therapeutics, Inc since March 02, 2022 and Neurogene Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Rohan Palekar
CEO & Director7.3yrsUS$7.62m0.25%
$ 5.7m
Ryan Martins
Chief Financial Officer6.3yrsUS$3.42m0.11%
$ 2.6m
Francis Sarena
Chief Operating Officer1.2yrsUS$2.99m0.0082%
$ 189.1k
Quoc Le-Nguyen
Chief Technical Officer6.6yrsUS$3.67m0.084%
$ 1.9m
Harry Mansbach
Chief Medical Officer6.8yrsUS$3.69m0.084%
$ 1.9m
Shiva Natarajan
Senior Vice President of Finance & Principal Accounting Officerno datano datano data
Annie Chang
VP of Investor Relations & Corporate Communications1.9yrsno datano data
Amanda Kurihara
Vice President of People & Culture4.8yrsno datano data
Melissa Abel
Senior Vice President of Commercial Strategyno datano datano data
Michael Baldwin
Senior VP & Head of Quality2.8yrsno datano data
Teresa Perney
Chief Regulatory & Quality Officer1.1yrsno datano data
Nancy Vinh
Senior Vice President of Clinical Operationsless than a yearno datano data
3.8yrs
Average Tenure
58yo
Average Age

Experienced Management: ETNB's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rohan Palekar
CEO & Director7.3yrsUS$7.62m0.25%
$ 5.7m
Kathleen LaPorte
Independent Director3.9yrsUS$398.34k0%
$ 0
Lota Zoth
Independent Director5.2yrsUS$399.97k0%
$ 0
Michael Hayden
Independent Director7.5yrsUS$392.47k0.16%
$ 3.7m
Martin Babler
Independent Director1.5yrsUS$489.25k0%
$ 0
Steven Altschuler Buser
Independent Chairman of the Board5.6yrsUS$419.97k0%
$ 0
Charles McWherter
Independent Director1.3yrsUS$440.25kno data
Edward Atkinson
Independent Director3.7yrsUS$388.72k0%
$ 0
Derek DiRocco
Independent Director7.5yrsUS$383.72k0%
$ 0
5.2yrs
Average Tenure
63yo
Average Age

Experienced Board: ETNB's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/29 06:45
End of Day Share Price 2025/10/29 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

89bio, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamCitigroup Inc
Liisa BaykoEvercore ISI
null nullEvercore ISI